News | February 18, 2009

GE Installs First Series of Discovery PET/CT 600 Series Scanners

February 18, 2009 – GE Healthcare said the new Discovery PET/CT 600-series scanners, designed to help enable earlier detection and accurate monitoring of disease, are being installed globally.

The first clinical installs will be completed at: Miami Baptist Hospital in Florida; University Hospital of Bichat in Paris, France; Queensland X-Ray at the Mater Hospital in Brisbane, Australia; Duke University Medical Center in North Carolina; and Mayo Clinic in Minnesota.

The new PET/CT platform was built based on clinician needs for more power to explore the potential of PET/CT imaging that includes better PET quantitative accuracy, according to GE. This new line of PET/CT scanners, combine advanced molecular imaging tools with the large coverage low dose Volume CT helping allow for earlier diagnosis, more accurate tumor location and better assessment of how a patient is responding to cancer treatment. Although mostly for use in oncology, PET/CT can also be used for assisting the diagnosis of cardiovascular disease and neurological conditions.

The new system leverages the high-speed, high-resolution capabilities of GE’s advanced CT, the LightSpeed VCT. Volume CT technology, with 40 mm of coverage, reduces CT acquisition times and CT dose. Static organs can be imaged in as little as one second, the lung in as little as two seconds and a whole body trauma could be performed in less than 10 seconds.

GE's next generation of MotionFree imaging technologies are introduced in the new Discovery 600 series PET/CT, giving clinicians detailed images even in areas of the body subject to movement caused by respiration. GE's MotionFree imaging technologies are integrated with VUE Point FX, an advanced high-definition reconstruction technique. Combined, these technologies have the potential to improve small lesion detection, image quality, and better therapy response monitoring.

By combining the LightSpeed VCT with the breakthrough motion management capabilities of the Discovery PET system, the new Discovery PET/CT platform provides the next evolution PET/CT system, bringing clinically-relevant innovations designed to open doors to new and advanced procedure possibilities in non-invasive diagnostic imaging.

For more information: www.gehealthcare.com

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init